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preparative regimen consisting of busulfan, cyclophosphamide,
and anti-thymocyte globulin for a 5 out of 6 HLA-antigen-
matched unrelated donor cord blood transplant. Graft-versus-
host disease (GVHD) prophylaxis consisted of cyclosporine and
methylprednisolone, and the patient experienced isolated acute
skin GVHD. Notably, several astrocytoma lesions regressed or
decreased in size between 3 and 8 months after transplantation,
associated with a lymphocytic CSF pleiocytosis with elevated
CSF protein. The patient remains leukemia-free with stable
brain lesions 25 months after transplantation. This case illus-
trates the potential for donor-derived immune cells to control
brain tumors, and suggests that allogeneic bone marrow trans-
plantation may represent an important immunotherapeutic
strategy for the aggressive treatment of poor-prognosis brain
tumors. Future clinical protocols should seek to further charac-
terize the nature of the immune response to brain tumors after
allogeneic bone marrow transplantation.
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USE OF CHROMATIN MODIFYING AGENTS FOR EX VIVO EXPANSION OF
HUMAN UMBILICAL CORD BLOOD STEM CELLS
Hoffman, R.1, Hiroto, A.1, Mahmud, N.1 University of Illinois at
Chicago, Chicago, IL.
The ﬁxed number of hematopoietic stem cells (HSCs) within a
single cord blood (CB) unit has limited the use of CB for allogeneic
transplantation in adults. Efforts to promote self-renewal and ex-
pansion of HSCs have been met with limited success. Using pres-
ently available ex vivo culture techniques, HSCs lose their func-
tional properties in proportion to the number of cellular divisions
they have undergone. We hypothesized that chromatin modifying
agents, 5-aza-2-deoxycytidine (5azaD) and histone deacetylase
inhibitor, trichostatin A (TSA) could reactivate pivotal genes re-
quired for retaining the functional properties of dividing HSC to
permit transplantation of adults. A 12.5-fold expansion was ob-
served in the 5azaD/TSA treated CD34CD90 cell cultures
containing SCF, thrombopoietin, and FLT3 ligand (cytokines) in
comparison to the input cell number. Despite 9 days of culture,
35.4%  5.8% (n  10) of the total cells in the cultures exposed to
chromatin modifying agents were CD34 CD90 compared to
1.40%  0.32% in the culture containing cytokines alone. The
CD34CD90 cells were associated with a 9.8-fold increase in
the numbers of CFU-mix and 11.5-fold expansion of cobblestone
area-forming cells (CAFC). The frequency of SCID repopulating
cells (SRC) was 1 in 26,537 in primary CB CD34CD90 cells
but was increased to 1 in 2745 CD34CD90 cells following 9
days of culture in the presence of 5azaD/TSA resulting in a 9.6-
fold expansion of the number of SRC. In contrast, the cultures
lacking 5azaD/TSA had a net loss of both CFC/CAFC as well as
SRC. The expansion of cells maintaining CD34CD90 pheno-
type was not due to the retention of a quiescent population of cells
since all of the CD34CD90 cells in the culture had undergone
cellular division. CD34CD90 cells that had undergone 5–10
cellular divisions in the presence of 5azaD/TSA but not in the
absence still retained the ability to repopulate NOD/SCID mice.
We next assessed the effect of 5azaD/TSA treatment on the ex-
pression of HOX-B4, a transcription factor which has been impli-
cated in HSC self-renewal. A signiﬁcantly higher level of HOXB4
protein was detected by western blot analysis after 9 days of culture
in the cells treated with 5azaD/TSA as compared to cells exposed
to cytokines alone. The almost 10-fold increase in SRC achieved
using the chromatin modifying agents may be sufﬁcient to increase
the numbers of engraftable HSC within a single human CB unit for
adult recipients.
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ADULT HUMAN HEMATOPOIETIC CELLS DIFFERENTIATE INTO MATURE
T CELLS VIA A CD3-48- INTERMEDIATE WITHIN THE MOUSE THYMIC
MICROENVIRONMENT; A NEW MODEL SYSTEM FOR THE STUDY OF
HUMAN THYMOCYTE DEVELOPMENT FURTHER ENHANCED BY ANTI-
MURINE c-Kit mAB
Kraft, D.L.1, Czechowicz, A.1, Weissman, I.I.1 Stanford University
Depts of Pediatric Hematology/Oncology and Pathology, Stanford, CA.
Normal T cell differentiation occurs within the thymus. We
previously found that human thymocyte precursors develop via
a novel CD3-48- intermediate population, utilizing SCID-hu
thymic grafts (Kraft,Weissman,Waller;JEM). We have recently
worked to develop a more convenient robust model of human
hematopoiesis utilizing RAG2/Common Gamma Chain double
KO mice transplanted with hematopoietic progenitor cells from
adult human donors, and hypothesized that human engraftment
would be enhanced by selective inhibition of murine hemato-
poisis by administration of anti-murine c-Kit mAb. Methods:
Mobilized CD34 cells from healthy adults were obtained to
	90% purity by CliniMacs. 2–8  105 CD34 cells were
injected intrahepatically into newborn RAG2 DKO pups fol-
lowing 4Gy of irradiation. At serial time points, human CD45
chimerism was measured within the recipient marrow, blood,
spleen, liver, lymph node, and thymus. A subset of recipients
were treated with the anti-murine c-Kit mAb (ACK2) starting at
D 14. Results: Human engraftment was detectable in CD34
transplanted mice, and this was enhanced by suppression of
murine hematopoiesis by anti c-Kit mAb. Robust human thy-
mopoeisis was observed. A mean of 63% of cells within the
thymus were human derived. At earlier time points (4–6 weeks
post transplant) the recipient thymus were found to contain high
fractions of CD45CD348 cells (making up 30–40% of
human cells within the thymus) and the CD348 (20–30%)
and CD48 (30–70%) intermediate populations with very
rare mature CD348 or CD348 T cells. At later time
points the fraction of immature CD348 and CD348
populations declined and increasing populations of mature
CD348 and CD34-8 populations were identiﬁed in
distributions similar to a normal thymus. Conclusions: Human
T cell development appears to progress normally within a mu-
rine thymic microenvironment. The early development of a
CD348 intermediate suggests that T cell development
occurs via this population, unlike the CD348 intermediate
found in mice thymopoesis, suggesting that the pathway of
human T cell differentiation is intrinisic to the human thymo-
cytes, and is independent of whether the thymic stroma is
human or murine. This robust model system enabling study of
human thymopoesis utilizing hematopoietic stem cells from
normal and diseased adults human donors may provide signiﬁ-
cant advantages for the study of human intrathymic T cell
differentiation and function in vivo.
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CD8/TCR GRAFT FACILITATING CELLS ENHANCE HSC FUNCTION VIA
INDUCTION OF LOW LEVELS OF TNF-	
Ildstad, S.T.1, Rezzoug, F.1, Huang, Y.1, Wysoczynski, M.2,
Schanie, C.L.1, Ratajczak, M.Z.2, Fugier-Vivier, I.J.1 1. Institute for
Cellular Therapeutics, University of Louisville, Louisville, KY; 2. Stem
Cell Biology Program at James Brown Cancer Center, University of
Louisville, Louisville, KY.
Approaches to enhance engraftment of HSC when cell num-
bers are limiting remain an elusive goal in bone marrow trans-
plantation. We recently reported that CD8/TCR facilitating
cells (FC), a subpopulation of BM cells containing predomi-
nantly B220/CD11c/CD11b tolerogenic precursor-plasma-
cytoid dendritic cells, enhance HSC engraftment in allogeneic
recipients. FC are themselves tolerogenic, directly preventing
GVHD. Additionally, FC signiﬁcantly enhance engraftment of
limiting numbers of HSC in syngeneic recipients. In the present
studies, we investigated the mechanism of FC function. Here we
show for the ﬁrst time that FC signiﬁcantly increase HSC
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